使用米氮平治疗焦虑

J. Begert, Bridget Bradley
{"title":"使用米氮平治疗焦虑","authors":"J. Begert, Bridget Bradley","doi":"10.9740/MHC.2015.11.265","DOIUrl":null,"url":null,"abstract":"Abstract Introduction: Currently, mirtazapine is only approved for use in patients with major depressive disorder, yet the unique dual mechanism of action for this agent has led many to inquire about potential alternative uses. The purpose of this article is to review the evidence available and evaluate the efficacy and tolerability of mirtazapine for use in patients presenting with various forms of anxiety. Methods: A search of the medical literature using Ovid Medline and the search terms “mirtazapine” and “anxiety disorders” resulted in the identification of 12 trials and 1 meta-analysis investigating off-label mirtazapine use in various subsets of anxiety. Results: Upon review of the literature, mirtazapine was found to perform significantly better than placebo at controlling symptoms of anxiety with comorbid depression, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder; and with comparable efficacy, in some cases with significantly better respon...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"11 1","pages":"265-270"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Off-label use of mirtazapine for anxiety\",\"authors\":\"J. Begert, Bridget Bradley\",\"doi\":\"10.9740/MHC.2015.11.265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Introduction: Currently, mirtazapine is only approved for use in patients with major depressive disorder, yet the unique dual mechanism of action for this agent has led many to inquire about potential alternative uses. The purpose of this article is to review the evidence available and evaluate the efficacy and tolerability of mirtazapine for use in patients presenting with various forms of anxiety. Methods: A search of the medical literature using Ovid Medline and the search terms “mirtazapine” and “anxiety disorders” resulted in the identification of 12 trials and 1 meta-analysis investigating off-label mirtazapine use in various subsets of anxiety. Results: Upon review of the literature, mirtazapine was found to perform significantly better than placebo at controlling symptoms of anxiety with comorbid depression, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder; and with comparable efficacy, in some cases with significantly better respon...\",\"PeriodicalId\":18691,\"journal\":{\"name\":\"Mental Health Clinician\",\"volume\":\"11 1\",\"pages\":\"265-270\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Clinician\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9740/MHC.2015.11.265\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/MHC.2015.11.265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

摘要简介:目前,米氮平仅被批准用于重度抑郁症患者,但该药物独特的双重作用机制导致许多人质疑其潜在的替代用途。本文的目的是回顾现有的证据,并评估米氮平用于各种形式焦虑患者的疗效和耐受性。方法:使用Ovid Medline检索医学文献,搜索词“米氮平”和“焦虑症”,结果确定了12项试验和1项荟萃分析,调查了米氮平在各种焦虑症亚群中的超适应症使用。结果:通过文献回顾,发现米氮平在控制伴有共病抑郁、创伤后应激障碍、广泛性焦虑障碍、惊恐障碍和社交焦虑障碍的焦虑症状方面明显优于安慰剂;具有相当的疗效,在某些情况下有明显更好的反应……
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Off-label use of mirtazapine for anxiety
Abstract Introduction: Currently, mirtazapine is only approved for use in patients with major depressive disorder, yet the unique dual mechanism of action for this agent has led many to inquire about potential alternative uses. The purpose of this article is to review the evidence available and evaluate the efficacy and tolerability of mirtazapine for use in patients presenting with various forms of anxiety. Methods: A search of the medical literature using Ovid Medline and the search terms “mirtazapine” and “anxiety disorders” resulted in the identification of 12 trials and 1 meta-analysis investigating off-label mirtazapine use in various subsets of anxiety. Results: Upon review of the literature, mirtazapine was found to perform significantly better than placebo at controlling symptoms of anxiety with comorbid depression, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder; and with comparable efficacy, in some cases with significantly better respon...
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pharmacologic treatment of bipolar disorder and comorbid adult attention-deficit/hyperactivity disorder Training student pharmacists to administer long-acting injectable medications AAPP 2024 Annual Meeting Poster Abstracts Clozapine clinical toolkit optimizes inpatient clozapine monitoring Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1